By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Myovant 



Hamilton  Bermuda    United Kingdom
Phone: n/a Fax: n/a


SEARCH JOBS

Myovant Sciences is focused on innovative treatments for women's health conditions and prostate cancer. The company's lead program is relugolix, a phase 3 drug candidate for multiple indications, including uterine fibroids, endometriosis and prostate cancer. Myovant was formed through a strategic partnership between Roivant Sciences and Takeda.

YEAR FOUNDED:

2016

LEADERSHIP:

CEO: Lynn Seely

CFO: Frank Karbe

JOBS:

Please click here for Myovant Sciences job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Private

Web Site: Myovant
Employees:
Symbol: MYOV
 



Industry
Pharmaceutical






Company News
Myovant (MYOV) Provides Corporate Update And Reports Financial Results For First Fiscal Quarter Ended June 30, 2017 8/11/2017 12:00:37 PM
Myovant (MYOV) Bolsters Executive Team With Key Management Appointments 7/20/2017 10:07:42 AM
Myovant (MYOV) Initiates Phase III Clinical Program Of Relugolix In Women With Endometriosis-Associated Pain 6/29/2017 7:23:21 AM
Myovant (MYOV) Announces Presentation Of Data At The European Congress Of Endocrinology From Phase ll Extension Study Evaluating Relugolix In Women With Endometriosis-Associated Pain 5/24/2017 8:09:48 AM
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Endometriosis-Associated Pain At The World Congress On Endometriosis 5/22/2017 6:53:18 AM
Myovant (MYOV) Announces Upcoming Presentations Of Relugolix Data From Phase II Trial In Women With Endometriosis-Associated Pain 5/18/2017 6:46:49 AM
Myovant (MYOV) Announces Presentation Of Positive Phase II Data For Relugolix In Women With Heavy Menstrual Bleeding And Uterine Fibroids At The Annual Meeting Of The American Congress Of Obstetricians And Gynecologists 5/8/2017 6:31:47 AM
Myovant (MYOV) Initiates Phase III Clinical Trial Of Relugolix In Men With Advanced Prostate Cancer 3/2/2017 6:32:46 AM
Myovant Release: Initiates Phase 3 Clinical Program Of Relugolix In Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids 1/25/2017 8:22:19 AM
Myovant Appoints Terrie Curran To Board Of Directors 11/16/2016 10:18:21 AM
12
//-->